An Update from Larimar Therapeutics
In a press release and corporate presentation this morning, September 29. 2025, Larimar Therapeutics announced positive data from ongoing long-term open label study and updates to nomlabofusp program for Friedreich’s ataxia (FA).
Larimar observed increases in frataxin protein and improved clinical outcomes relative to the FACOMS reference population in the individuals who have maintained nomlabofusp therapy. Larimar also provided an update on the safety and tolerability highlighting the risk for anaphylaxis.
